

13 March 2026

**PureTech Health plc**

**PDMR Notifications**

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that the award of restricted share units ("RSUs") granted by PureTech on 22 May 2023 to a certain person discharging managerial responsibilities ("PDMR") pursuant to its Performance Share Plan ("PSP") vested on 11 March 2026 following satisfaction of certain performance conditions measured over the three year period to 31 December 2025.

The PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 12 March 2026. The market price per ordinary share in the Company used to calculate the amount payable to the PDMR and the amount of shares to be issued to the PDMR was 123.67 pence, being the average closing price of the Company's shares over the three-trading day period immediately preceding the vesting date, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: 1.34.

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMR, 14,859,738 shares of which are held in treasury by the Company.

**PDMR Notification**

*The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.*

|          |  |  |                         |
|----------|--|--|-------------------------|
| <b>1</b> | <b>Details of the person discharging managerial responsibilities/person closely associated</b>   |  |                         |
| a)       | Name   | Eric Elenko  |                         |
| <b>2</b> | <b>Reason for the notification</b>   |  |                         |
| a)       | Position/status  | President  |                         |
| b)       | Initial notification/Amendment   | Initial Notification   |                         |
| <b>3</b> | <b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>   |  |                         |
| a)       | Name   | PureTech Health plc  |                         |
| b)       | LEI  | 213800LVPDNO2Z9T9I39   |                         |
| <b>4</b> | <b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b> |  |                         |
| a)       | Description of the financial instrument, type of instrument  | Ordinary Shares of PureTech Health plc<br>ISIN GB00BY2Z0H74  |                         |
| b)       | Nature of the transaction  | Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes. |                         |
| c)       | Price(s) and volume(s)   | <b>Recipient</b>   | <b>Price</b>            |
|          |  | <b>Amount</b>  |                         |
|          |  | Eric Elenko  | 0.01 GBP                |
|          |  | 112,509 ordinary shares  |                         |
| d)       | Aggregated information<br>-Aggregated volume<br>- Price  | <b>Price</b>   | <b>Aggregate Volume</b> |
|          |  | 0.01 GBP   | 112,509 ordinary shares |
|          |  |  |                         |
| e)       | Date of the transaction  | 12 March 2026  |                         |
| f)       | Place of the transaction   | London Stock Exchange (XLON)   |                         |

**About PureTech Health**

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit [www.puretechhealth.com](http://www.puretechhealth.com) or connect with us on X (formerly Twitter) @puretechh.

**Contact:**

PureTech

**Pure Tech**

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHG PurawupQGRP